Protease inhibitors and erectile dysfunction
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Increasing numbers of HIV-positive men receiving protease inhibitors (PI) complain of erectile dysfunction (ED). Through the analysis of 334 HIV-1-infected male outpatients, this study shows homosexuality, CD4 cell count, viral load, and indinavir treatment to be independent variables predictive of ED. Furthermore, a neuropathy of the sacral region was detected in 12 patients with ED who underwent diagnostic investigations. For the first time, a PI-containing regimen has been associated with peripheral neuropathy causing ED. Increasing numbers of HIV-positive men receiving protease inhibitors (PI) as part of highly active antiretroviral therapy have complained of erectile dysfunction (ED) [1,2]. We aimed at investigating the role of PI in the development of ED and the pathophysiological mechanisms underlying this disorder. This two-stage study was carried out between March 1999 and March 2000. All patients with a history of mental disorders (or taking any antidepressants), liver dysfunction, diabetes mellitus, hypertension, or current alcohol or drug abuse were excluded from the study. In the first stage, 500 consecutive HIV-1-infected male outpatients aged 18–45 years attending our department were invited to fill in a screening questionnaire asking whether they suffered from ED and, if so, the date of onset of the disorder and if they would undergo diagnostic assessments. No information about the purpose of the study was given. Other sexual problems were not investigated. Data on the patients completing the questionnaire (age, HIV risk factor, AIDS diagnosis, CD4 cell count, plasma HIV-RNA level, and antiretroviral treatment) were collected. They refer to the time of the administration of the questionnaire in the case of patients without ED and to the time of onset of the disorder in the case of those with ED. All statistical analyses were performed using the SPSS 9.0 for Windows 98 software package. Between-group statistical significances were determined using Pearson's χ2 test. A logistic regression was performed in multivariate analysis to estimate the relative risks of progression for each above-mentioned variable included in the model. In the second stage, patients with ED who provided written informed consent underwent diagnostic investigations, including psychiatric, hormonal, neurophysiological, and vascular assessments [3–5]. The psychiatric evaluations were based on two self-completed questionnaires: the symptom check list 90 – revised, consisting of 90 items assessing general psychopathology, and the Beck depression inventory, consisting of 21 items investigating the symptoms of depression [6,7]. The hormonal assessments included measurements of serum-free testosterone, luteinizing hormone, follicle-stimulating hormone, and prolactin levels. The neurophysiological investigations included bulbocavernosus reflex (BCR) measurements, pudendal and tibial nerve somatosensory evoked potential (p–tSSEP) recordings, tibial and sural nerve electroneurographic (t–sENG) studies, and nocturnal penile tumescence (NPT) monitoring [8–13]. The vascular assessments were based on penile colour Doppler ultrasonography after an intracavernous injection of 20 μg prostaglandin E1 [14]. General laboratory tests were also performed, and the severity of ED measured according to the international index of erectile function [15]. Only 334 out of 500 HIV-1-infected male outpatients (67%, with a median age of 36 years) completed the screening questionnaire. Their characteristics were as follows: age 36 years or less/over 36 years: 178 (53%)/156 (47%); HIV risk factor: intravenous drug users 175 (52%), homosexual 74 (22%), heterosexual 72 (22%), other 13 (4%); with/without AIDS diagnosis: 58 (17%)/276 (83%); median CD4 cell count: 431 cells/μl (range 1–1279); HIV-RNA level less than 5000/5000 or greater copies/ml: 250 (75%)/84 (25%); PI-receiving/non-PI-receiving: 251 (75%)/83 (25%). ED was reported by 30 out of 334 patients; specifically, by 24 out of 251 PI-receiving (10%) and six out of 83 non-PI-receiving (7%). Therefore, 24 out of 30 patients with ED (80%) were on treatment with PI. Considering the PI used by the patients with or without ED, indinavir was taken by 21 (70%) out of 130 (43%), and nelfinavir by three (10%) out of 82 (27%); ritonavir and hard-gel saquinavir were seldom used and usually given in combination with other PI in both groups. Of the 83 non-PI-receiving patients, 18 (22%) were treatment naive and 65 (78%) received a PI-sparing regimen including two nucleoside reverse transcriptase inhibitors with or without a non-nucleoside reverse transcriptase inhibitor. Only one out of 18 naive patients (6%) had ED, as against five out of 65 on a PI-sparing regimen (8%). Neither the antiretroviral regimens (naive, PI-sparing, PI-including), nucleoside reverse transcriptase inhibitors (specifically, lamivudine and stavudine, the two most frequently used), nor non-nucleoside reverse transcriptase inhibitors were si
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lue, T. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422407 · Cited by 1,252
(1999) · doi:10.1016/s0090-4295(99)00099-0 · Cited by 1,051
Cited by
Male sexual dysfunction and HIV – A clinical perspective
Santi, D., Brigante, G., Zona, S., Guaraldi, G., & Rochira, V. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2013.314 · Cited by 56
Factors associated with erectile dysfunction among men living with HIV: a systematic review
Huntingdon, B., Muscat, D. M., de Wit, J., Duracinsky, M., & Juraskova, I. (2020) · AIDS Care · doi:10.1080/09540121.2019.1653443 · Cited by 21
De Vincentis, S., Decaroli, M. C., Milic, J., Fanelli, F., Tartaro, G., Diazzi, C., Mezzullo, M., De Santis, M. C., Roli, L., Trenti, T., et al. (2023) · Andrology · doi:10.1111/andr.13372 · Cited by 14
Metadata
- Authors
- Sollima, S., Osio, M., Muscia, F., Gambaro, P., Alciati, A., Zucconi, M., Maga, T., Adorni, F., Bini, T., & d'Arminio Monforte, A.
- Venue
- AIDS
- Published
- 2001-11
- Volume
- 15
- Issue
- 17
- Pages
- 2331-2333
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2325494025
- Cited by
- 48
- References
- 2
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protease inhibitors and erectile dysfunction. https://app.cochat.ai/papers/10.1097/00002030-200111230-00020
- The paper
- Sollima, S., Osio, M., Muscia, F., Gambaro, P., Alciati, A., Zucconi, M., Maga, T., Adorni, F., Bini, T., & d'Arminio Monforte, A. (2001). Protease inhibitors and erectile dysfunction. AIDS. https://doi.org/10.1097/00002030-200111230-00020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.